{"DataElement":{"publicId":"7414963","version":"1","preferredName":"Disposition Domain Unevaluable Study End Point Type","preferredDefinition":"An indicator for the study endpoint for which patient was declared inevaluable.","longName":"SUPPDS_QVAL_DSENPT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7414956","version":"1","preferredName":"Disposition Domain Unevaluable Study End Point","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disposition._Unable to be evaluated._A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it._A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","longName":"2859364v1.0:7414954v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2859364","version":"1","preferredName":"Disposition Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disposition.","longName":"C49576","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disposition Domain","conceptCode":"C49576","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disposition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"667C7B15-C9BA-53A6-E040-BB89AD43558C","latestVersionIndicator":"Yes","beginDate":"2009-04-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-04-01","modifiedBy":"ONEDATA","dateModified":"2009-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7414954","version":"1","preferredName":"Unevaluable Study End Point","preferredDefinition":"Unable to be evaluated.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","longName":"C62222:C63536:C25212","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Study","conceptCode":"C63536","definition":"A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"End Point","conceptCode":"C25212","definition":"A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFC6C17-4957-6D86-E053-4EBD850ACA14","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008521","version":"1","preferredName":"Protocol","preferredDefinition":"a clinical trial protocol","longName":"PROTOCOL","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B03417B5-806E-1DA8-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-11-24","endDate":null,"createdBy":"NILANDJ","dateCreated":"2002-11-24","modifiedBy":"DWARZEL","dateModified":"2022-08-31","changeDescription":"Capitalized protocol to Protocol - DW 08-31","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFC6C17-4968-6D86-E053-4EBD850ACA14","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"SETRAKIN","dateModified":"2020-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7414957","version":"1","preferredName":"Study Endpoint Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7414957v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEFE7AD0-33DE-049B-E053-4EBD850A39AA","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","deletedIndicator":"No"},{"value":"Overall Survival","valueDescription":"Overall Survival","ValueMeaning":{"publicId":"7414959","version":"1","preferredName":"Overall Survival","longName":"7414959","preferredDefinition":"A measure of the time until death from any cause.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overall Survival","conceptCode":"C125201","definition":"A measure of the time until death from any cause.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFE7AD0-33EA-049B-E053-4EBD850A39AA","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEFE7AD0-3405-049B-E053-4EBD850A39AA","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","deletedIndicator":"No"},{"value":"Event-free Survival","valueDescription":"Event-Free Survival","ValueMeaning":{"publicId":"7414960","version":"1","preferredName":"Event-Free Survival","longName":"7414960","preferredDefinition":"The length of time after treatment during which a patient survives with no sign of a particular complication of disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Event-Free Survival","conceptCode":"C96340","definition":"The length of time after treatment during which a patient survives with no sign of a particular complication of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFE7AD0-340F-049B-E053-4EBD850A39AA","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEFE7AD0-342A-049B-E053-4EBD850A39AA","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","deletedIndicator":"No"},{"value":"Response or MRD negative second remission status","valueDescription":"Minimal Residual Disease Negative Second Remission Disease Response","ValueMeaning":{"publicId":"7414961","version":"1","preferredName":"Minimal Residual Disease Negative Second Remission Disease Response","longName":"7414961","preferredDefinition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.: Involving disadvantage or harm.: A unit of time, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour.: An abatement in intensity or degree (as in the manifestations of a disease).: The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Negative","conceptCode":"C25247","definition":"Involving disadvantage or harm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Second","conceptCode":"C42535","definition":"A unit of time, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFE7AD0-343A-049B-E053-4EBD850A39AA","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEFE7AD0-3455-049B-E053-4EBD850A39AA","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","deletedIndicator":"No"},{"value":"Dose-limiting toxicities","valueDescription":"Regimen-Limiting Toxicity","ValueMeaning":{"publicId":"7414962","version":"1","preferredName":"Regimen-Limiting Toxicity","longName":"7414962","preferredDefinition":"A side effect of a drug or other treatment that is serious enough to necessitate a dose modification.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regimen-Limiting Toxicity","conceptCode":"C123282","definition":"A side effect of a drug or other treatment that is serious enough to necessitate a dose modification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFE7AD0-345F-049B-E053-4EBD850A39AA","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEFE7AD0-347A-049B-E053-4EBD850A39AA","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"ONEDATA","dateModified":"2020-09-10","deletedIndicator":"No"},{"value":"Best Overall Response","valueDescription":"Best Overall Response","ValueMeaning":{"publicId":"6618826","version":"1","preferredName":"Best Overall Response","longName":"6618826","preferredDefinition":"The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best Overall Response","conceptCode":"C94536","definition":"The most clinically favorable response recorded from the start of the study treatment until the end of treatment.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"804A1D9D-3F71-3C2A-E053-F662850A9CA8","latestVersionIndicator":"Yes","beginDate":"2019-01-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-25","modifiedBy":"ONEDATA","dateModified":"2019-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3AF6018-B473-3CDA-E053-4EBD850AFFAC","beginDate":"2020-11-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-09","modifiedBy":"ONEDATA","dateModified":"2020-11-09","deletedIndicator":"No"},{"value":"Patient is not eligible","valueDescription":null,"ValueMeaning":{"publicId":"4259213","version":"1","preferredName":"Patient Ineligibility","longName":"4259213v1.00","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The state or quality of being disqualified by law, rule, or provision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ineligibility","conceptCode":"C40412","definition":"The state or quality of being disqualified by law, rule, or provision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5EEE383-E072-7BDA-E040-BB89AD431D71","latestVersionIndicator":"Yes","beginDate":"2014-03-31","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-31","modifiedBy":"MMADDINENI","dateModified":"2022-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB01A441-C419-2AEB-E053-731AD00A609C","beginDate":"2022-10-14","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-14","modifiedBy":"MMADDINENI","dateModified":"2022-10-14","deletedIndicator":"No"},{"value":"Not all required PK samples were collected","valueDescription":null,"ValueMeaning":{"publicId":"11453713","version":"1","preferredName":"Negation All Requirement Pharmacokinetics Specimen collection","longName":"11453713v1.00","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._To a complete degree or to the full or entire extent._Something that is a necessary condition; something that is obligatory._The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._The act of gathering things together; having been brought together in one place.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"All","conceptCode":"C64916","definition":"To a complete degree or to the full or entire extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Requirement","conceptCode":"C25652","definition":"Something that is a necessary condition; something that is obligatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pharmacokinetics","conceptCode":"C15299","definition":"The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Collection","conceptCode":"C25453","definition":"The act of gathering things together; having been brought together in one place.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB01A441-C418-2AEB-E053-731AD00A609C","latestVersionIndicator":"Yes","beginDate":"2022-10-14","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-14","modifiedBy":"MMADDINENI","dateModified":"2022-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB01A441-C41A-2AEB-E053-731AD00A609C","beginDate":"2022-10-14","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-14","modifiedBy":"MMADDINENI","dateModified":"2022-10-14","deletedIndicator":"No"},{"value":"PK sample not collected at appropriate time point","valueDescription":null,"ValueMeaning":{"publicId":"11480136","version":"1","preferredName":"Pharmacokinetics Specimen Negation Collection Reference Time Point","longName":"11480136v1.00","preferredDefinition":"The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._An operation in which a term denies or inverts the meaning of another term or construction._The act of gathering things together; having been brought together in one place._The point in time that acts as a fixed reference point to an event.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacokinetics","conceptCode":"C15299","definition":"The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Collection","conceptCode":"C25453","definition":"The act of gathering things together; having been brought together in one place.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reference Time Point","conceptCode":"C82576","definition":"The point in time that acts as a fixed reference point to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB67BBFA-E568-19BF-E053-731AD00AE304","latestVersionIndicator":"Yes","beginDate":"2022-10-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-19","modifiedBy":"MMADDINENI","dateModified":"2022-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB67BBFA-E569-19BF-E053-731AD00AE304","beginDate":"2022-10-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-19","modifiedBy":"MMADDINENI","dateModified":"2022-10-19","deletedIndicator":"No"},{"value":"Response at end of Induction","valueDescription":null,"ValueMeaning":{"publicId":"12406511","version":"1","preferredName":"Response at end of Induction","longName":"12406511v1.00","preferredDefinition":"The point or place at which something terminates in time, space, or extent._The first choice of treatment for a particular type of cancer._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Induction Therapy","conceptCode":"C158876","definition":"The first choice of treatment for a particular type of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2A0C3A6-D93E-7F31-E053-731AD00A6075","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-19","modifiedBy":"KUMMEROA","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2A0C3A6-D940-7F31-E053-731AD00A6075","beginDate":"2023-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-19","modifiedBy":"KUMMEROA","dateModified":"2023-01-19","deletedIndicator":"No"},{"value":"Response at end of Consolidation","valueDescription":null,"ValueMeaning":{"publicId":"12406512","version":"1","preferredName":"Response at end of Consolidation","longName":"12406512v1.00","preferredDefinition":"The point or place at which something terminates in time, space, or extent._Treatment that is given after initial therapy to kill any remaining cancer cells._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Consolidation Therapy","conceptCode":"C15679","definition":"Treatment that is given after initial therapy to kill any remaining cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2A0C3A6-D93F-7F31-E053-731AD00A6075","latestVersionIndicator":"Yes","beginDate":"2023-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-19","modifiedBy":"KUMMEROA","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2A0C3A6-D941-7F31-E053-731AD00A6075","beginDate":"2023-01-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-01-19","modifiedBy":"KUMMEROA","dateModified":"2023-01-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008521","version":"1","preferredName":"Protocol","preferredDefinition":"a clinical trial protocol","longName":"PROTOCOL","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B03417B5-806E-1DA8-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-11-24","endDate":null,"createdBy":"NILANDJ","dateCreated":"2002-11-24","modifiedBy":"DWARZEL","dateModified":"2022-08-31","changeDescription":"Capitalized protocol to Protocol - DW 08-31","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFE7AD0-33C8-049B-E053-4EBD850A39AA","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"KUMMEROA","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":"2023.1.19 PVs added per ticket request CADSR0001936. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"SUPPDS_QVAL_DSENPT","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Which study endpoint(s) was t","type":"Preferred Question Text","description":"Which study endpoint(s) was the patient considered inevaluable for?","url":null,"context":"COG"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Reason patient is not evaluable for PK analysis:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEFE881E-C441-106C-E053-4EBD850AAF48","latestVersionIndicator":"Yes","beginDate":"2020-09-10","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-10","modifiedBy":"KUMMEROA","dateModified":"2023-01-19","changeDescription":null,"administrativeNotes":"2023.1.19 Alt SN added per ticket request CADSR0001936. ak","unresolvedIssues":null,"deletedIndicator":"No"}}